Bioprocessing beat, packaging broke — Repligen surged on a raised guide while Corning's post-earnings plunge dragged the pharma-glass chokepoint, with 100% pharma tariffs now days away.

Repligen led the vertical, up 10.9% to $145.34, on a Q2 that reset the growth debate. Revenue came in at $204 million, up roughly 13% organically and ahead of the ~$201.5 million consensus, non-GAAP EPS of $0.54 beat the $0.46 estimate, and management raised full-year organic growth to 10.5%–13.5% and adjusted EPS to $2.03–$2.09. Repligen sits at the bioprocessing chokepoint — the filtration, chromatography and single-use consumables that sit inside the manufacture of nearly every biologic — so an acceleration here is read as a real-time gauge of biopharma production demand, not just one company's quarter. The market took it as confirmation the consumables cycle has turned back up.

Corning was the mirror image: −12.1% to $126.01 on roughly 46 million shares, about triple its normal volume, despite beating. Core EPS of $0.78 topped the $0.75 estimate on revenue of $4.74 billion, up 17%, and the company guided a strong third quarter — but the stock had run into the print and the setup gave way. Corning anchors the pharma-packaging chokepoint through its Valor pharmaceutical glass, though the selloff was company-wide across display, optical and solar rather than a vials-specific event. On a tape already hostile to anything priced for perfection, a beat-and-raise was not enough to hold the valuation.

The rest of the lab-tools and bioprocessing complex caught Repligen's updraft. Charles River rose 7.2% to $240.43 — a CRO-and-tools rebound, not earnings, with its own report not due until August 5 — while Amphastar gained 5.1%, Mettler-Toledo 4.6% to $1,388.38, Baxter 4.4% to $24.37, Waters 3.4%, Thermo Fisher 3.0% to $576.41, ICU Medical 2.7% and Agilent 1.9%. Losers beyond Corning were few and shallow, led by Becton's ADR line at −2.3%. For a supply-chain vertical, the pattern was constructive: the consumables and instruments chokepoints firmed while the pain stayed concentrated in a single packaging name's valuation.

The calendar now collides with policy. Section 232 pharmaceutical tariffs — reported at 100% on patented pharma and active ingredients, with carve-outs for generics, biosimilars and orphan drugs — take effect July 31, the vertical's single largest near-term catalyst and a direct test of how much reshoring pressure actually reaches the API chokepoint. Samsung Biologics reports Q2 today (July 29), Mettler-Toledo and Baxter both land July 30, and Waters follows on August 4 as the first full quarter of the combined Waters/BD entity. Those prints, framed by the tariff deadline, will show whether Repligen's reacceleration is the sector's signal or its exception.